What are BPC-157’s main benefits?
What are BPC-157’s main drawbacks?
BPC-157’s potential drawbacks are uncertain, given the lack of human evidence. No clear toxicity or negative side effects have been reported in studies conducted in rodents,[4][5][1] but this research is limited. Therefore, the biggest drawback of BPC-157 is that there is insufficient evidence of its safety.
How does BPC-157 work?
BPC-157 has various possible (potentially overlapping) mechanisms of action, including promoting nitric oxide synthesis, activating cells involved in tissue repair, stimulating the synthesis of growth factors, and inhibiting inflammation.[2][6][7]
BPC-157 can be taken orally, topically, or via injection. Oral ingestion of peptides like BPC-157 wouldn’t normally be expected to have a direct effect on tissues outside of the gastrointestinal tract (like tendons and nerves) because peptides aren’t easily absorbed into circulation. However, studies in rodents have suggested that oral ingestion can have systemic effects, meaning that the feasibility of this route of delivery can’t be ruled out.[8]
What is BPC-157?
Body Protection Compound 157 (BPC-157) is a peptide composed of 15 amino acids. Although the researchers who patented BPC-157 say that it was derived from a stomach protein, this claim isn’t well-substantiated.[9] BPC-157 is thought to improve the repair of damaged tissues, although there is currently no human evidence to support this hypothesis.[1]
What are other names for BPC-157
- PL 14736
- PL-10
- Bepecin
- TB-500
Dosage information
The closest possible recommended dose is based on rat studies where oral administration showed benefit, as most studies administer the supplement via injection. The oral dose that was effective in rats, 10 μg/kg, is estimated to be equivalent to 1.6 μg/kg, or:
- 110 μg for a 150lb person
- 145 μg for a 200lb person
- 180 μg for a 250lb person
There are currently no human pharmacokinetic studies to assess species differences.
Frequently asked questions
BPC-157’s potential drawbacks are uncertain, given the lack of human evidence. No clear toxicity or negative side effects have been reported in studies conducted in rodents,[4][5][1] but this research is limited. Therefore, the biggest drawback of BPC-157 is that there is insufficient evidence of its safety.
BPC-157 has various possible (potentially overlapping) mechanisms of action, including promoting nitric oxide synthesis, activating cells involved in tissue repair, stimulating the synthesis of growth factors, and inhibiting inflammation.[2][6][7]
BPC-157 can be taken orally, topically, or via injection. Oral ingestion of peptides like BPC-157 wouldn’t normally be expected to have a direct effect on tissues outside of the gastrointestinal tract (like tendons and nerves) because peptides aren’t easily absorbed into circulation. However, studies in rodents have suggested that oral ingestion can have systemic effects, meaning that the feasibility of this route of delivery can’t be ruled out.[8]
Body Protection Compound 157 (BPC-157) is a peptide composed of 15 amino acids. Although the researchers who patented BPC-157 say that it was derived from a stomach protein, this claim isn’t well-substantiated.[9] BPC-157 is thought to improve the repair of damaged tissues, although there is currently no human evidence to support this hypothesis.[1]
Update History
Corrected an error
Research written by
Research Breakdown
References
- ^Gwyer D, Wragg NM, Wilson SLGastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.Cell Tissue Res.(2019-Aug)
- ^Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Stambolija V, Zoricic Z, Vrcic H, Sebecic BFocus on ulcerative colitis: stable gastric pentadecapeptide BPC 157Curr Med Chem.(2012)
- ^Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić PPentadecapeptide BPC 157 and the central nervous system.Neural Regen Res.(2022-Mar)
- ^Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Safic H, Suran J, Rak D, Dzidic S, Vrcic H, Sebecic BToxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157.Curr Pharm Des.(2013)
- ^Deek SABPC 157 as Potential Treatment for COVID-19.Med Hypotheses.(2021-Nov-09)
- ^Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHThe promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationJ Appl Physiol (1985).(2011 Mar)
- ^Japjec M, Horvat Pavlov K, Petrovic A, Staresinic M, Sebecic B, Buljan M, Vranes H, Giljanovic A, Drmic D, Japjec M, Prtoric A, Lovric E, Batelja Vuletic L, Dobric I, Boban Blagaic A, Skrtic A, Seiwerth S, Predrag SStable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats.Biomedicines.(2021-Oct-27)
- ^Sven Seiwerth, Marija Milavic, Jaksa Vukojevic, Slaven Gojkovic, Ivan Krezic, Lovorka Batelja Vuletic, Katarina Horvat Pavlov, Andrea Petrovic, Suncana Sikiric, Hrvoje Vranes, Andreja Prtoric, Helena Zizek, Tajana Durasin, Ivan Dobric, Mario Staresinic, Sanja Strbe, Mario Knezevic, Marija Sola, Antonio Kokot, Marko Sever, Eva Lovric, Anita Skrtic, Alenka Boban Blagaic, Predrag SikiricStable Gastric Pentadecapeptide BPC 157 and Wound HealingFront Pharmacol.(2021 Jun 29)
- ^Sikirić P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, Turković B, Jagić V, Mildner B, Duvnjak MA new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC.J Physiol Paris.(1993)
